Lista de obras - John B. Porter - Dominio Público Uruguay

6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium

artículo científico publicado en 1999

A direct method for quantification of non-transferrin-bound iron

artículo científico publicado en 1990

A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry

artículo científico publicado en 2014

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.

artículo científico publicado en 2010

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

artículo científico publicado en 2007

A retrospective observational study of pre-operative sickle cell screening

artículo científico publicado en 2002

A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity

artículo científico publicado en 1998

Animal toxicology of iron chelator L1

artículo científico publicado en 1989

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

artículo científico publicado en 2014

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan

artículo científico publicado en 2014

Blood transfusion: quality and safety issues in thalassemia, basic requirements and new trends

artículo científico publicado en 2009

Calibration of myocardial T2 and T1 against iron concentration.

artículo científico publicado en 2014

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload

artículo científico publicado en 2001

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association

artículo científico publicado en 2013

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes

artículo científico publicado en 2001

Challenges of adherence and persistence with iron chelation therapy

scientific article published on 13 October 2011

Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay

artículo científico publicado en 2016

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

artículo científico publicado en 2011

Combined chelation therapy with deferasirox and deferoxamine in thalassemia ⬇️

artículo científico publicado el 11 de noviembre de 2012

Concepts and goals in the management of transfusional iron overload.

artículo científico publicado en 2007

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

artículo científico publicado en 2010

Coronary artery bypass graft surgery in a patient with haemoglobin SC disease

artículo científico publicado en 2001

Cross-talk between available guidelines for the management of patients with beta-thalassemia major

artículo científico publicado en 2013

Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma

artículo científico publicado en 2007

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients ⬇️

artículo científico publicado el 13 de mayo de 2013

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

artículo científico publicado en 2013

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

artículo científico publicado en 2012

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

artículo científico publicado en 2012

Deferasirox--current knowledge and future challenges

artículo científico publicado en 2010

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.

artículo científico

Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs

artículo científico publicado en 2005

Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators

artículo científico publicado en 2002

Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance

artículo científico publicado en 2016

Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method

scientific article published on 01 May 2000

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

artículo científico publicado en 2015

Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice

artículo científico publicado en 2014

Effect of green tea on iron status and oxidative stress in iron-loaded rats.

artículo científico publicado en 2008

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

artículo científico publicado en 2007

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

artículo científico publicado en 2015

Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice

artículo científico publicado en 2010

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

artículo científico publicado en 2012

Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.

artículo científico publicado en 2009

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia

artículo científico publicado en 2009

Endothelial activation in patients with chronic venous disease

artículo científico publicado en 1998

Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study

artículo científico publicado en 1999

Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress

artículo científico publicado en 2007

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].

artículo científico publicado en 2008

Facilitated uptake of zinc into human erythrocytes. Relevance to the treatment of sickle-cell anaemia

scientific article published on 01 March 1990

Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes

artículo científico publicado en 2001

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias

artículo científico publicado en 2012

Granulocytic sarcomas of small intestine and brain are associated with acute myelomonocytic leukaemia with abnormal eosinophils and inversion of chromosome 16.

artículo científico publicado en 1992

HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients

scientific article published on 01 July 1994

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

artículo científico publicado en 2012

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

artículo científico publicado en 2013

Hepcidin and iron species distribution inside the first-trimester human gestational sac ⬇️

artículo científico publicado el 22 de diciembre de 2010

Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.

artículo científico publicado en 2014

High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major

scientific article published on 14 March 2014

Images in cardiovascular medicine. Superior vena cava occlusion by cardiovascular magnetic resonance.

artículo científico

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years

artículo científico publicado en 2011

Increased leucocyte apoptosis in transfused β‐thalassaemia patients ⬇️

artículo científico publicado el 6 de diciembre de 2012

Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents

artículo científico publicado en 1990

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.

artículo científico publicado en 2013

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials

artículo científico

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

artículo científico publicado en 2010

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

artículo científico publicado en 2011

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies

artículo científico publicado en 2010

Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction

artículo científico publicado en 2009

Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major

artículo científico publicado en 2005

Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease

artículo científico publicado en 1997

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

artículo científico publicado en 2011

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

artículo científico publicado en 2010

Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.

artículo científico publicado en 2014

Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy

artículo científico publicado en 2008

Monitoring and treatment of iron overload: state of the art and new approaches.

artículo científico publicado en 2005

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

artículo científico publicado en 2004

Myocardial iron quantification using T2* and native T1mapping - a 250 patient study

Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy

scientific article published on 01 September 2007

Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera

artículo científico publicado en 2007

New insights into transfusion-related iron toxicity: Implications for the oncologist

artículo científico publicado en 2015

Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload.

artículo científico

Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron

scientific article published on 01 June 2007

On T2* magnetic resonance and cardiac iron

artículo científico publicado en 2011

On myocardial siderosis and left ventricular dysfunction in hemochromatosis.

artículo científico publicado en 2013

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study

artículo científico publicado en 2015

Optimizing iron chelation strategies in beta-thalassaemia major.

artículo científico publicado en 2009

Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

artículo científico publicado en 2006

Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.

artículo científico publicado en 2009

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

artículo científico publicado en 2008

Perforation of superior vena cava by indwelling central venous catheters

artículo científico publicado en 1987

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state

artículo científico publicado en 2010

Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes

artículo científico publicado en 1994

Practical management of iron overload.

artículo científico publicado en 2001

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study

artículo científico publicado en 2014

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia

scientific article published on 01 May 2007

Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome

artículo científico publicado en 2012

Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection

scientific article published on 01 May 1992

Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin

artículo científico publicado en 1999

Raised haematocrit concentration and the risk of death and vascular complications after major surgery.

artículo científico publicado en 2013

Red blood cell-derived microparticles: An overview

artículo científico publicado en 2016

Relation of myocardial T2* to right ventricular function in thalassaemia major

artículo científico publicado en 2010

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

artículo científico publicado en 2011

Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform

artículo científico publicado en 2005

Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids

artículo científico publicado en 2011

Sample acceptance time criteria, electronic issue and alloimmunisation in thalassaemia.

artículo científico publicado en 2015

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

artículo científico publicado en 2015

Secondary erythrocytosis due to compound homozygosity, but not compound heterozygosity, for Hb Luton and α-thalassemia: a family study.

artículo científico publicado en 2012

Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models

artículo científico publicado en 1988

Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest

artículo científico publicado en 1998

Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids

artículo científico publicado en 1990

Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase

artículo científico publicado en 2001

Sudden exertional death in sickle cell trait.

artículo científico publicado en 2011

Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

artículo científico publicado en 2014

Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update.

artículo científico publicado en 2016

Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort.

artículo científico publicado en 2010

Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.

artículo científico publicado en 2015

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

artículo científico publicado en 2009

The Iliad as Oral Formulaic Poetry

a book by John Porter

The development of hydroxypyridin-4-ones as orally active iron chelators

artículo científico

The development of iron chelating drugs

artículo científico publicado en 1989

The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.

artículo científico publicado en 1997

The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators

scientific article published on 01 April 1996

The pathophysiology of transfusional iron overload

artículo científico publicado en 2014

The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase

scientific article published on 01 August 1996

The toxic effects of desferrioxamine

artículo científico publicado en 1989

The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload

scientific article published on 01 May 2000

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

artículo científico publicado en 2011

Transfusion and chelation practices in sickle cell disease: a regional perspective

artículo científico publicado en 2010

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone

artículo científico publicado en 2013

Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World: The TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR).

artículo científico publicado en 2016

Ultrashort echo time (UTE) MRI of the spine in thalassaemia

scientific article published on 01 February 2004

Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.

artículo científico

Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major

artículo científico publicado en 2004

Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.

artículo científico publicado en 2010

Lista de obras de John B. Porter

6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium

A direct method for quantification of non-transferrin-bound iron

A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

A retrospective observational study of pre-operative sickle cell screening

A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity

Animal toxicology of iron chelator L1

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan

Blood transfusion: quality and safety issues in thalassemia, basic requirements and new trends

Calibration of myocardial T2 and T1 against iron concentration.

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes

Challenges of adherence and persistence with iron chelation therapy

Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Combined chelation therapy with deferasirox and deferoxamine in thalassemia ⬇️

Concepts and goals in the management of transfusional iron overload.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Coronary artery bypass graft surgery in a patient with haemoglobin SC disease

Cross-talk between available guidelines for the management of patients with beta-thalassemia major

Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients ⬇️

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Deferasirox--current knowledge and future challenges

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.

Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs

Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators

Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance

Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice

Effect of green tea on iron status and oxidative stress in iron-loaded rats.

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia

Endothelial activation in patients with chronic venous disease

Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease--a prospective study

Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].

Facilitated uptake of zinc into human erythrocytes. Relevance to the treatment of sickle-cell anaemia

Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias

Granulocytic sarcomas of small intestine and brain are associated with acute myelomonocytic leukaemia with abnormal eosinophils and inversion of chromosome 16.

HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

Hepcidin and iron species distribution inside the first-trimester human gestational sac ⬇️

Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.

High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major

Images in cardiovascular medicine. Superior vena cava occlusion by cardiovascular magnetic resonance.

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years

Increased leucocyte apoptosis in transfused β‐thalassaemia patients ⬇️

Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies

Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction

Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major

Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.

Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy

Monitoring and treatment of iron overload: state of the art and new approaches.

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

Myocardial iron quantification using T2* and native T1mapping - a 250 patient study

Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy

Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera

New insights into transfusion-related iron toxicity: Implications for the oncologist